Ocular Therapeutix, Inc. (NASDAQ:OCUL) is Knoll Capital Management LLC's 10th Largest Position

Knoll Capital Management LLC increased its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 199.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 600,400 shares of the biopharmaceutical company's stock after buying an additional 400,000 shares during the period. Ocular Therapeutix accounts for about 2.6% of Knoll Capital Management LLC's portfolio, making the stock its 10th largest position. Knoll Capital Management LLC owned 0.39% of Ocular Therapeutix worth $5,223,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OCUL. Atlas Capital Advisors LLC bought a new stake in Ocular Therapeutix during the 2nd quarter valued at $34,000. Amalgamated Bank raised its holdings in shares of Ocular Therapeutix by 37.9% in the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company's stock valued at $37,000 after acquiring an additional 1,481 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Ocular Therapeutix by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 1,015 shares during the period. Algert Global LLC purchased a new stake in Ocular Therapeutix in the second quarter worth about $69,000. Finally, Capital Performance Advisors LLP bought a new position in Ocular Therapeutix during the 3rd quarter worth about $70,000. Institutional investors own 59.21% of the company's stock.

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 2,948 shares of the firm's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $9.01, for a total transaction of $26,561.48. Following the sale, the insider now directly owns 269,059 shares of the company's stock, valued at $2,424,221.59. This trade represents a 1.08 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on OCUL shares. HC Wainwright boosted their price target on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a "buy" rating in a report on Friday, November 15th. Scotiabank began coverage on shares of Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $22.00 price objective for the company. Finally, Robert W. Baird lowered their target price on Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating for the company in a report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.71.

Ocular Therapeutix Stock Down 1.7 %

OCUL traded down $0.17 during trading on Friday, hitting $9.89. The stock had a trading volume of 775,830 shares, compared to its average volume of 1,828,064. The stock has a 50 day simple moving average of $9.98 and a two-hundred day simple moving average of $8.27. The company has a market capitalization of $1.55 billion, a PE ratio of -7.49 and a beta of 1.26. Ocular Therapeutix, Inc. has a twelve month low of $2.44 and a twelve month high of $11.77. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.